Immunogenicity studies to support variant-targeted changes in current COVID-19 vaccines should demonstrate that the modified product generates immune response rates not more than 10% below those of the original vaccine, the US Food and Drug Administration said.
In an updated guidance document on emergency use authorization for COVID-19 vaccines, the agency lays out a streamlined regulatory...







